IP Library Granted Patent US 8,853,358
Granted Patent B2
US 8,853,358 · App. 12/863,973 · Granted Oct 7, 2014

Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Inventors: Anthony Cerami (Ossining, NY); Michael Brines (Woodbridge, CT)
Assignee: Araim Pharmaceuticals, Inc.
C07K14/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,853,358
App. No.
12/863,973
Granted
Oct 7, 2014
Kind
B2
Abstract

The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoietic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.

Claims (6)

1. An isolated peptide consisting of the amino acid sequence XEQLERALNSS (SEQ ID NO: 282), wherein X is pyroglutamate.

2. A pharmaceutical composition comprising a purified peptide and a pharmaceutically acceptable carrier, wherein the purified peptide consists of the amino acid sequence XEQLERALNSS (SEQ ID NO: 282), wherein X is pyroglutamate.

3. The pharmaceutical composition of claim 2 , wherein said purified peptide is produced by chemical synthesis and has less than about 5% by dry weight of chemical precursors or compounds other than the purified peptide.

4. An isolated peptide modified with an addition of polyethylene glycol, wherein said peptide consists of the amino acid sequence XEQLERALNSS (SEQ ID NO: 282), wherein X is pyroglutamate.

5. A pharmaceutical composition comprising a purified peptide and a pharmaceutical carrier, wherein the purified peptide is modified with an addition of polyethylene glycol, and wherein the purified peptide consists of the amino acid sequence XEQLERALNSS (SEQ ID NO: 282), wherein X is pyroglutamate.

6. The pharmaceutical composition of claim 5 , wherein said purified peptide is produced by chemical synthesis and has less than about 5% by dry weight of chemical precursors or compounds other than the purified peptide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2014
From: CERAMI, ANTHONY; BRINES, MICHEAL
To: ARAIM PHARMACEUTICALS, INC.
Reel/Frame 033675/0348 →
Continuity (6)
Provisional Application 61062012 · Jan 22, 2008
Provisional Application 61062022 · Jan 22, 2008
Provisional Application 61062045 · Jan 22, 2008
Provisional Application 61133912 · Jul 3, 2008
Provisional Application 61203890 · Dec 30, 2008
Related Publication 20110263504A1 · Oct 27, 2011